Vital Therapies, Inc. is a biotherapeutic company that has been developing a cell-based therapy targeting the treatment of acute forms of liver failure.  The Company’s ELAD® System, an extracorporeal human allogeneic cellular liver therapy, recently reported top-line data from its phase 3 clinical trial in severe alcoholic hepatitis.  Although there was a numerical improvement in survival in the ELAD-treated group between three months and one year following randomization, the study failed to meet the primary endpoint of a significant improvement in overall survival through at least ninety-one days assessed using the Kaplan Meier statistical method.  The secondary endpoint of the proportion of survivors at study day ninety-one also showed no statistically significant difference between the groups.

In light of these results, the Company does not believe the ELAD System can be approved in the United States or European Union, if ever, without additional clinical trials that would require substantial capital and time to complete.  Consequently, the Company has ceased any further development of the ELAD System and is exploring strategic options.

Note Regarding Forward-Looking Statements: Certain statements found on this website may be forward looking in nature or constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “believe,” “expects,” “estimates” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in the forward-looking statements. A number of those risks and uncertainties are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s annual report on Form 10-K. Any forward-looking statements should be evaluated in light of these important risk factors. The Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.